A Long-Term Clinical Study of TS-071 as Monotherapy in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 17 May 2017
Price : $35 *
At a glance
- Drugs Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 24 Mar 2016 Pooled analysis (n=1031) of 4 trials - JapicCTI111507, JapicCTI111508, JapicCTI111509, and JapicCTI111543 were published in the Clinical Therapeutics.
- 02 Oct 2013 New source identified and integrated: Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information.
- 26 Sep 2013 Results reported at 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), according to a Taisho Pharmaceutical Holdings media release.